Continuation of TRAVERSE- LTS12551 Evaluating Dupilumab Safety in Patients With Asthma (Long-Term Follow-Up)
Public ClinicalTrials.gov record NCT03620747. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Open-label, Interventional, Cohort Study to Evaluate Long-term Safety of Dupilumab in Patients With Moderate to Severe Asthma Who Completed the TRAVERSE-LTS12551 Clinical Trial
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Primary Objective: To describe the long-term safety of dupilumab in treatment of participants with moderate to severe asthma who completed the previous asthma clinical trial (TRAVERSE-LTS12551).
Study identification
- NCT ID
- NCT03620747
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 393 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 12 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 30, 2018 (Actual)
- Primary completion
- Feb 18, 2022 (Actual)
- Completion
- Feb 18, 2022 (Actual)
- Last update posted
- Mar 16, 2023
2018 – 2022
United States locations
- U.S. sites
- 35
- U.S. states
- 21
- U.S. cities
- 33
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigational Site Number :840099 | Gilbert | Arizona | 85234 | — |
| Investigational Site Number :840087 | Scottsdale | Arizona | 85248 | — |
| Investigational Site Number :840402 | Tucson | Arizona | 85721 | — |
| Investigational Site Number :840132 | Little Rock | Arkansas | 72209 | — |
| Investigational Site Number :840121 | San Jose | California | 95117 | — |
| Investigational Site Number :840403 | Denver | Colorado | 80206 | — |
| Investigational Site Number :840130 | Denver | Colorado | 80246 | — |
| Investigational Site Number :840115 | Ocoee | Florida | 34761 | — |
| Investigational Site Number :840055 | Sarasota | Florida | 34239 | — |
| Investigational Site Number :840079 | Twin Falls | Idaho | 83301 | — |
| Investigational Site Number :840032 | Fort Mitchell | Kentucky | 41017 | — |
| Investigational Site Number :840064 | Bangor | Maine | 04401 | — |
| Investigational Site Number :840052 | Chevy Chase | Maryland | 20815 | — |
| Investigational Site Number :840073 | Gaithersburg | Maryland | 20878 | — |
| Investigational Site Number :840018 | Minneapolis | Minnesota | 55402 | — |
| Investigational Site Number :840102 | St Louis | Missouri | 63141 | — |
| Investigational Site Number :840004 | Papillion | Nebraska | 27103 | — |
| Investigational Site Number :840068 | West Long Branch | New Jersey | 07764 | — |
| Investigational Site Number :840126 | Charlotte | North Carolina | 28277 | — |
| Investigational Site Number :840907 | High Point | North Carolina | 27262 | — |
| Investigational Site Number :840942 | Toledo | Ohio | 43617 | — |
| Investigational Site Number :840067 | Philadelphia | Pennsylvania | 19140 | — |
| Investigational Site Number :840091 | Pittsburgh | Pennsylvania | 15241 | — |
| Investigational Site Number :840070 | Allen | Texas | 75013 | — |
| Investigational Site Number :840062 | Amarillo | Texas | 79109 | — |
| Investigational Site Number :840124 | Cypress | Texas | 77429 | — |
| Investigational Site Number :840023 | Dallas | Texas | 75231 | — |
| Investigational Site Number :840922 | Fort Worth | Texas | 76109 | — |
| Investigational Site Number :840027 | Fort Worth | Texas | 76244 | — |
| Investigational Site Number :840008 | San Antonio | Texas | 78229 | — |
| Investigational Site Number :840035 | Draper | Utah | 84020 | — |
| Investigational Site Number :840077 | Murray | Utah | 84107 | — |
| Investigational Site Number :840057 | South Burlington | Vermont | 05403 | — |
| Investigational Site Number :840059 | Fairfax | Virginia | 22030 | — |
| Investigational Site Number :840951 | Bellingham | Washington | 98225 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 97 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03620747, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 16, 2023 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03620747 live on ClinicalTrials.gov.